(+/-)-ethyl 3-(4-((4-methoxybenzyl)oxy)phenyl)hex-4-ynoate | 865233-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (+/-)-ethyl 3-(4-((4-methoxybenzyl)oxy)phenyl)hex-4-ynoate
• 英文别名: (+/-)-[4-(4-methoxy-benzyloxy)-phenyl]-hex-4-ynoic acid ethyl ester；Ethyl 3-[4-[(4-methoxyphenyl)methoxy]phenyl]hex-4-ynoate
• CAS: 865233-39-2
• 化学式: C₂₂H₂₄O₄
• 分子量: 352.43
• InChiKey: YIZYGXUAXFSCIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+/-)-ethyl 3-(4-((4-methoxybenzyl)oxy)phenyl)hex-4-ynoate 在 caesium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  AMG 837: A potent, orally bioavailable GPR40 agonist

  摘要：

  The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of beta-substituted phenylpropanoic acids led to the identification of (S)-3-(44(4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.118
• 作为产物：
  描述：

  4-[(4-甲氧基苯基)甲氧基]苯甲醛 在 哌啶 、 4-二甲氨基吡啶 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.25h， 生成 (+/-)-ethyl 3-(4-((4-methoxybenzyl)oxy)phenyl)hex-4-ynoate
  参考文献：
  名称：

  AMG 837: A potent, orally bioavailable GPR40 agonist

  摘要：

  The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of beta-substituted phenylpropanoic acids led to the identification of (S)-3-(44(4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.118

文献信息

• Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
  申请人：Akerman Michelle

  公开号：US20060004012A1

  公开（公告）日：2006-01-05

  The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L 1 -P-L 2 -M-X-L 3 -A wherein the definitions of the variables Q, L 1 , P, L 2 , M, X, L 3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

  本发明提供了一种有用的化合物，例如，用于调节受试者体内胰岛素水平的化合物，其具有以下一般公式 Q-L1-P-L2-M-X-L3-A 其中变量Q、L1、P、L2、M、X、L3和A的定义在此处提供。本发明还提供了用于这些化合物的组合物和方法，例如，用于治疗2型糖尿病。
• COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS
  申请人：Amgen, Inc

  公开号：EP1737809B1

  公开（公告）日：2013-09-18
• US7649110B2
  申请人：——

  公开号：US7649110B2

  公开（公告）日：2010-01-19
• US7816367B2
  申请人：——

  公开号：US7816367B2

  公开（公告）日：2010-10-19
• AMG 837: A potent, orally bioavailable GPR40 agonist
  作者：Jonathan B. Houze、Liusheng Zhu、Ying Sun、Michelle Akerman、Wei Qiu、Alex J. Zhang、Rajiv Sharma、Michael Schmitt、Yingcai Wang、Jiwen Liu、Jinqian Liu、Julio C. Medina、Jeff D. Reagan、Jian Luo、George Tonn、Jane Zhang、Jenny Ying-Lin Lu、Michael Chen、Edwin Lopez、Kathy Nguyen、Li Yang、Liang Tang、Hui Tian、Steven J. Shuttleworth、Daniel C.-H. Lin

  DOI：10.1016/j.bmcl.2011.10.118

  日期：2012.1

  The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of beta-substituted phenylpropanoic acids led to the identification of (S)-3-(44(4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents. (C) 2011 Elsevier Ltd. All rights reserved.